Dormant
QNST · QuinStreet, Inc.
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 18 September 2026; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Current thesis
QuinStreet's carrier-advertising recovery must translate into September-quarter guidance delivery and a price recovery before a weekly close below $17. Northland's 2026-09-17 target increase renews analyst support, but the 2026-09-18 close of $17.55 leaves market confirmation unresolved.
Kill line
A weekly close below $17 ends the post-results price-recovery thesis at the previously identified July breakout area. Separately, fiscal Q1 revenue below $370 million, adjusted EBITDA below $38 million, or reduced fiscal 2027 guidance would break the operating case.
Pick status
Open commitment catalyst in 2dscored if the kill line above fires How this is scored →Latest analysis and events for QNST —
As of 20 September 2026, the latest FrontierPicks analysis for QuinStreet, Inc. (QNST): QuinStreet's carrier-advertising recovery must translate into September-quarter guidance delivery and a price recovery before a weekly close below $17. Northland's 2026-09-17 target increase renews analyst support, but the 2026-09-18 close of $17.55 leaves market confirmation unresolved.
Kill line: A weekly close below $17 ends the post-results price-recovery thesis at the previously identified July breakout area. Separately, fiscal Q1 revenue below $370 million, adjusted EBITDA below $38 million, or reduced fiscal 2027 guidance would break the operating case.
Next dated event on file: — catalyst in 2d.
Current Thesis
QuinStreet's carrier-advertising recovery thesis depends on meeting its September-quarter guidance while preserving the market's $17 weekly-close threshold. The operating test remains the fiscal first-quarter revenue guidance of $370–380 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) guidance of $38–40 million, published on 2026-08-06. QuinStreet earnings release
The material change since the 2026-09-06 assessment is renewed analyst support alongside a lower share price. Northland Securities analyst Michael Grondahl raised his target to $23 from $21 on 2026-09-17, according to Stock Analysis. That supersedes the earlier finding that target revisions had stalled; it does not establish broader participation. Grondahl rating history
The supplied adjusted market series records a 2026-09-18 close of $17.55, compared with $18.73 on 2026-09-04. The narrative is maturing — the 2026-08-06 operating results now have a fresh 2026-09-17 target increase behind them, but the latest close remains below the earlier September reference close. This is an inference from the dated operating, analyst and price evidence; the limited observations cannot establish whether institutional or retail participation has widened.
Bullish and bearish views on QuinStreet, Inc.
The model's bull view on QuinStreet, Inc. (QNST), in brief: Earnings grew faster than revenue. QuinStreet reported fiscal fourth-quarter revenue of $373.9 million, up 43% year over year, and adjusted EBITDA of $41.4 million, up 87%, on 2026-08-06. These measured results support the margin-expansion component of the recovery thesis.… The bear view: Price confirmation has weakened. The supplied adjusted bars show $17.55 on 2026-09-18 versus $18.73 on 2026-09-04. The latest close is 20.3% below the supplied $22.02 trailing-year high, despite a three-month price increase of 35.1%; the longer-window gain does not establish a… Both cases follow in full.
Bull Case
- Earnings grew faster than revenue. QuinStreet reported fiscal fourth-quarter revenue of $373.9 million, up 43% year over year, and adjusted EBITDA of $41.4 million, up 87%, on 2026-08-06. These measured results support the margin-expansion component of the recovery thesis. Company release
- The annual outlook supplies benchmarks. Management's 2026-08-06 fiscal 2027 guidance specified revenue of $1.45–1.55 billion and adjusted EBITDA of $150–160 million. Those are company forecasts, with the lower ends providing observable tests at subsequent results. Company release
- Analyst support has resumed. Grondahl's 2026-09-17 increase to a $23 target replaces Northland's earlier $21 target. The revision establishes renewed support from that analyst; the evidence is too limited to claim a market-wide reassessment. Stock Analysis
Bear Case
- Price confirmation has weakened. The supplied adjusted bars show $17.55 on 2026-09-18 versus $18.73 on 2026-09-04. The latest close is 20.3% below the supplied $22.02 trailing-year high, despite a three-month price increase of 35.1%; the longer-window gain does not establish a current recovery.
- Insider sales accompanied August strength. SEC Form 4 disclosures cited in the 2026-09-06 research record show CFO Gregory Wong selling on 2026-08-07 and 2026-08-18 under a Rule 10b5-1 trading plan, with director Asmau Ahmed reporting sales during 2026-08-11 through 2026-08-17. These are disclosed supply events, not evidence of the sellers' expectations for the next quarter.
- Acquisitions complicate the growth comparison. The 2026-08-06 segment disclosures recorded Home Services revenue of $141.6 million, up 88% year over year, without an organic-growth breakdown in the supplied record. That missing separation prevents the reported segment increase from independently establishing an organic run rate.
Setup & Price Structure
The 2026-09-18 adjusted close of $17.55 remains above the published $17 thesis threshold, which the 2026-09-06 note associated with the July breakout area. The earlier September reference close of $18.73 provides an observable recovery marker. A weekly close above $18.73 would establish a reclaim of that reference; a weekly close below $17 would invalidate the post-results price-recovery leg.
The supplied 14-day relative strength index (RSI) was 30.5 on 2026-09-18. No moving-average value, volume series, short-interest observation or retail-sentiment sample accompanies that reading. Neither distance above a rising average nor a crowded speculative trade can therefore be established.
The forecast has low conviction: the 2026-09-17 analyst revision strengthens the research case, while the 2026-09-18 close leaves the published price condition unresolved. The case would play out if fiscal first-quarter results meet the revenue and adjusted EBITDA guidance floors, management maintains or raises the annual ranges, and price records a weekly close above $18.73 before a weekly close below $17.
Catalyst Calendar (next 30 days)
- 2026-09-22 — Barrington investor conference. QuinStreet's 2026-08-12 announcement schedules management participation in the 19th Annual Barrington Research Virtual Fall Investment Conference. Any disclosed change to the 2026-08-06 outlook would bear directly on the thesis; the announcement itself promises no new financial results. Company conference announcement
- ~2026-11-05, estimated — Fiscal first-quarter results. This later event is included because it resolves the operating test. MarketBeat estimates the date from historical reporting schedules; it is not a company-confirmed appointment. Revenue below $370 million or adjusted EBITDA below $38 million would miss the respective floors of management's 2026-08-06 guidance. Earnings calendar
What Would Change Our Mind
Loss of the July breakout area would end the price-recovery case: a weekly close below $17 is the published thesis-break condition. The $17.55 close on 2026-09-18 does not itself meet that condition. Separately, fiscal first-quarter revenue below $370 million, adjusted EBITDA below $38 million, or a reduction in the fiscal 2027 outlook would contradict the operating expectations set on 2026-08-06.
The earlier conference test needs revision because Northland raised its target on 2026-09-17. Absence of any target increase is no longer an accurate objection. Evidence of a stronger recovery would require the stated operating tests and a weekly reclaim of the 2026-09-04 reference close of $18.73; another analyst target alone would not satisfy those conditions. Northland revision record
Correlation Notes
The supplied 2026-08-06 segment disclosures put Financial Services revenue at $232.3 million and auto-insurance revenue growth at 37% year over year. That exposure makes insurer customer-acquisition spending a plausible shared business driver with MediaAlpha and EverQuote.
The prior research record cites MediaAlpha's 2026-07-29 release showing quarterly revenue growth of 26% and EverQuote's 2026-08-03 results showing growth of 25%. These observations support a shared demand-cycle hypothesis, but the sample is too small to establish durable share-price correlation. This remains a single-name assessment: no measured group-price relationship supports the forecast, and QuinStreet's own guidance and $17 weekly-close condition determine its outcome.
Notes
- QuinStreet's fiscal year ends June 30. Fiscal Q1 2027 refers to the quarter ending September 2026; fiscal and calendar quarter labels are not interchangeable.
Related · shared themes
OSCR
Oscar Health, Inc.
Oscar Health's higher earnings outlook and quantified 2027 pricing support a post-Investor-Day rerating. A weekly close above $32.76 before a weekly close below $29.83 would complete the price-confirmation test; the September 18, 2026 close of $32.13 leaves it unresolved.
CNC
Centene Corporation
Centene's margin-repair case requires sustained earnings guidance and a weekly close above $68.72 by its 2026-10-27 results. September's reaffirmation supports the earnings leg, but a weekly close below $65 or withdrawal or reduction of fiscal 2026 adjusted EPS guidance above $4.80 invalidates the case.
HNGE
Hinge Health, Inc.
Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating insider selling mark a late, distribution-prone phase, with no company catalyst until the ~2026-08-04 Q2 print.
HUM
Humana Inc.
Humana's Medicare Advantage margin-recovery story faces a renewed price test: an adjusted daily close above $409.80 before a daily close below $383. The September 1, 2026 earnings reaffirmation supports stability, while October Star Ratings test the quality-bonus premise.
See also · stocks to watch